Activation of hedgehog (Hh) signaling contributes to the progression of
Barrett's esophagus (BE), which increases the risk of esophageal
adenocarcinoma. Recent clinical studies revealed that
proton-pump inhibitors (PPIs) but not H2 receptor antagonists (H2RAs) were associated with a decreased risk of esophageal
adenocarcinoma. We would like to know whether PPIs interfere with BE progression during BE treatment. Here, we explored the role of
omeprazole on Hh signaling and expression of two crucial
biomarkers of BE, SOX9 and CDX2. We demonstrated that
bile acids elevated expression of Hh pathway target genes, such as GLI1 and PTCH1, and induced SOX9 and CDX2 up-regulation in both CP-A and CP-B cells.
Omeprazole, but not
famotidine, down-regulated these genes induced by
bile acids. In addition,
omeprazole-induced down-regulation of SOX9 and CDX2 was mediated by Hh signaling. To explore the mechanisms by which
omeprazole inhibits Hh signaling, we performed
luciferase assay but did not find any effects of
omeprazole on the activity of GLI1 promoter, the critical
transcription factor of Hh signaling. Therefore, we used
miRNA sequencing and a bioinformatics tool in our study to identify the differently expressed
miRNAs in BE organoids treated with or without
omeprazole, and we identified miR-2116-3p was involved in
omeprazole-mediated inhibition of Hh signaling and subsequent down-regulation of SOX9 and CDX2. Collectively, our data indicate
omeprazole inhibits Hh signaling and subsequent SOX9 and CDX2 expression via up-regulating miR-2116-3p. We have demonstrated a novel
acid-independent mechanism of
omeprazole that might yield valuable insight into clinical management of BE progression, irrespective of
acid reflux symptoms.